Saturday, November 21, 2026

Xenetic Biosciences Stock 13.97% Up Today

ViaNews Editorial Team

January 29, 2024

Automated market report from our archive (2020-2024), published before source-traceability. How we work

Xenetic Biosciences Stock 13.97% Up Today

(VIANEWS) - The NASDAQ ended the session with Xenetic Biosciences (XBIO) jumping 13.97% to $3.53 on Monday while NASDAQ jumped 1.12% to $15,628.04.

Xenetic Biosciences's last close was $3.29, 56.17% under its 52-week high of $7.50.

About Xenetic Biosciences

Xenetic Biosciences, Inc., a biopharmaceutical company, focuses on advancing XCART, a personalized chimeric antigen receptor T cell (CAR T) platform technology engineered to target patient-specific tumor neoantigens. The company engages in the development of biologic drugs and therapeutics. It advances cell-based therapeutics targeting the B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. In addition, the company leveraging PolyXen, its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. It has collaboration agreements with Takeda Pharmaceutical Co. Ltd., Serum Institute of India Limited, and PJSC Pharmsynthez. Xenetic Biosciences, Inc. is headquartered in Framingham, Massachusetts.

Earnings Per Share

As for profitability, Xenetic Biosciences has a trailing twelve months EPS of $-2.9.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -34.98%.

Moving Average

Xenetic Biosciences's worth is above its 50-day moving average of $3.48 and below its 200-day moving average of $3.77.

Yearly Top and Bottom Value

Xenetic Biosciences's stock is valued at $3.53 at 17:12 EST, way below its 52-week high of $7.50 and way higher than its 52-week low of $2.55.

Revenue Growth

Year-on-year quarterly revenue growth grew by 47.5%, now sitting on 2.35M for the twelve trailing months.

More news about Xenetic Biosciences (XBIO).

Are you or your business in this article?

If something is wrong, out of context or missing, tell us. We correct errors with a dated note, and people named in an article can publish their response under it.

Correct, add context or respond →

Not a source? Spotted an error? Report an error

How this story was made

Spotted an error? Use “Correct this article” (bottom right), or select any sentence, to report it or respond to that point.

  1. Published before we listed source documents with each article.
  2. Published 29 Jan 2024
  3. No responses yet from the people or organisations in this story. Are you in this story? Respond on the record ›
  4. Part of the Via News record, fingerprinted daily so it cannot be quietly rewritten. What that means › · Report an error ›
ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.